HC Wainwright & Co. Initiates Coverage On DiaMedica Therapeutics with Buy Rating, Announces Price Target of $7
Benzinga Newsdesk 2 years ago
NewsPrice TargetInitiationAnalyst Ratings
HC Wainwright & Co. analyst Matthew Caufield initiates coverage on DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy rating and announces Price Target of $7.
HC Wainwright & Co. analyst Matthew Caufield initiates coverage on DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy rating and announces Price Target of $7.